Amgen Inc. / Rodeo Therapeutics Corporation

Inflammatory bowel disease (ulcerative colitis), idiopathic pulmonary fibrosis, and tissue regeneration (15-PGDH inhibition)

900K US cases/yr · $20.0B Global IBD biologics market 2021 (USD MM) · 100000 US patients with IPF

Disease Overview

15-prostaglandin dehydrogenase (15-PGDH) is the principal enzyme that degrades prostaglandin E2 (PGE2), a key signaling molecule for stem cell maintenance and tissue repair. Pharmacologic 15-PGDH inhibition raises endogenous PGE2 in damaged tissues, promoting regeneration of intestinal epithelium, lung parenchyma, hematopoietic stem cells and other compartments. The target indications collectively represent substantial unmet need: ulcerative colitis (UC) affects approximately 900,000 US patients with annual incidence of 8-12 per 100,000; Crohn's disease adds another 780,000 US patients; idiopathic pulmonary fibrosis (IPF) affects approximately 100,000 Americans with median survival of 3-5 years post-diagnosis. The global IBD market exceeded $20B in 2021 with TNF inhibitors (Humira, Remicade, Simponi), integrin antagonists (Entyvio), IL-12/23 (Stelara), IL-23 (Skyrizi, Tremfya, Omvoh), JAK inhibitors (Xeljanz, Rinvoq) and S1P modulators (Zeposia, Velsipity). Despite biologics, only 30-40% of UC patients achieve durable steroid-free remission, and primary/secondary non-response rates exceed 50% over 2-3 years. IPF therapy remains limited to nintedanib (Ofev, Boehringer Ingelheim) and pirfenidone (Esbriet, Roche/Genentech) — both anti-fibrotic but neither curative, with combined US sales >$2.5B in 2021.

Competitive Landscape

At deal date (March 2021), Rodeo's 15-PGDH inhibitor program was first-in-class with no direct competitors at clinical stage in the same enzymatic mechanism. Adjacent regenerative/anti-fibrotic competitors and IBD-targeted programs included: in IBD biologics — AbbVie's Humira (adalimumab, $20.7B 2021 global), Skyrizi (risankizumab IL-23 approved UC June 2024), Rinvoq (upadacitinib JAK1 approved UC March 2022); Janssen's Stelara (ustekinumab IL-12/23) and Tremfya (guselkumab IL-23 approved UC Sep 2024); Takeda's Entyvio (vedolizumab integrin); Eli Lilly's Omvoh (mirikizumab IL-23 approved UC Oct 2023); BMS's Zeposia (ozanimod S1P1/5 approved UC May 2021); Pfizer's Xeljanz (tofacitinib JAK), Velsipity (etrasimod S1P approved Oct 2023). In IPF — Boehringer Ingelheim Ofev/nintedanib (multi-tyrosine kinase, $3.4B 2022), Roche Esbriet/pirfenidone, BMS BMS-986278 (LPA1 antagonist Phase 3), United Therapeutics inhaled treprostinil (Tyvaso), Pliant Therapeutics bexotegrast (αvβ6/αvβ1 integrin Phase 2). In tissue regeneration/stem cell mobilization — Mesoblast (allogeneic MSC), Athersys (MultiStem), Magenta Therapeutics MGTA-145 (HSC mobilization, discontinued). Amgen's $721M Rodeo acquisition complemented its existing inflammation portfolio (Otezla, Tezspire/Amgen-AstraZeneca, Enbrel) with a regenerative-medicine MOA optionality.